Respiratory Medicine
Volume 96 , Pages S15-S24 , April 2002

Respiratory syncytial virus prophylaxis—the story so far

  • E.A.F. SIMOES

      Affiliations

    • Department of Paediatrics, Section of Infectious Diseases, The University of Colorado School of Medicine and The Children's Hospital, Denver, CO
    • Correspondence should be addressed to: Eric A.F. Simoes MD, DCH, 1056 East 19th Avenue Box B070, The Children's Hospital, Denver, CO 80218, USA
    • ,
  • J.R. GROOTHUIS

      Affiliations

    • Abbott Laboratories, Abbott Park, IL, U.S.A.

References 

    REFERENCES
  1. MMWR Morb Mortal Wkly Rep. 2000;49:1091–1093
  2. Heilman CA. From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis. 1990;161:402–406
  3. Hall CB. Respiratory syncytial virus. In:  Feigen RD,  Cherry JD editor. Textbook of Paediatric Diseases. Philadelphia: W. Saunders and Co; 1992;
  4. Garenne M, Ronsmans C, Campbell H. The magnitude of mortality from acute upper respiratory infections in children under 5 years in developing countries. World Health Stat Q. 1992;45:180–191
  5. Shay DK, Holman RC, Newman RD. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282:1440–1446
  6. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis. 2001;183:16–22
  7. Brandenburg AH, Jeannet PY, Steensel-Moll HA. Local variability in respiratory syncytial virus disease severity. Arch Dis Child. 1997;77:410–414
  8. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Paediatr. 1998;157:215–220
  9. Wang E EL, Law BJ, Stephens D. Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Paediatr. 1995;126:212–219
  10. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501–1507
  11. Hall CB, Hall WJ, Gala CL, MaGill FB, Leddy JP. Long-term prospective study in children after respiratory syncytial virus infection. J Paediatr. 1984;105:358–364
  12. Weber MW, Milligan P, Giadom B. Respiratory illness after severe respiratory syncytial virus disease in infancy in The Gambia. J Paediatr. 1999;135:683–688
  13. Simoes EA. Treatment and prevention of respiratory syncytial virus lower respiratory tract infection: Long-term effects on respiratory outcomes. Am J Respir Crit Care Med. 2001;163:S14–S17
  14. Fauroux B, Lacaze-Masmonteil T, Kimpen J LL. Respiratory syncytial virus: Clinical course and current treatment options. J Respir Dis. 2000;2:S4–S9
  15. Crowe JE, Englund JA. Future prevention strategies. In:  Weisman LE,  Groothuis JR editor. Contemporary Diagnosis and Management of Respiratory Syncytial Virus. Pennsylvania: Handbooks in Health Care Co; 2000;
  16. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Amer J Epid. 1969;89:405–421
  17. Kim HW, Canchola JG, Brandt CD. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Amer J Epid. 1969;89:422–434
  18. Karron RA, Wright PF, Crowe JE. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 1997;176:1428–1436
  19. Collins PL, Whitehead SS, Bukreyev A. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res. 1999;54:423–451
  20. Simoes E AF, Tan D HS, Ohlsson A, Sales V, Wang E EL. Respiratory Syncytial Virus Vaccine: A systematic overview with emphasis on RSV subunit vaccines. Vaccine. 2001;20:954–960
  21. Li X, Sambhara S, Li CX. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med. 1998;188:681–688
  22. Anderson LJ, Hierholzer JC, Tsou C. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis. 1985;151:626–633
  23. Ballow M, Cates KL, Rowe JC, Goetz C, Desbonnet C. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Paediatr Res. 1986;20:899–904
  24. Yeung CY, Hobbs JR. Serum-gamma-G-globulin levels in normal premature, post-mature, and “small-for-dates” newborn babies. Lancet. 1968;1:1167–1170
  25. Groothuis JR, Simoes E AF, Levin MJ. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524–1530
  26. Paediatrics. 1997;99:93–99
  27. Simoes EA, Sondheimer HM, Top FH. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Paediatr. 1998;133:492–499
  28. Weltzin R, Traina-Dorge V, Soike K. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis. 1996;174:256–261
  29. Meissner HC, Groothuis JR, Rodriguez WJ. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob Agents Chemother. 1999;43:1183–1188
  30. Johnson S, Griego SD, Pfarr DS. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis. 1999;180:35–40
  31. Johnson S, Oliver C, Prince GA. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215–1224
  32. Paediatrics. 1998;102:1211–1216
  33. Carbonell-Estrany X, Giuffré L, Kimpen J LL. Guidelines for the use of Synagis® (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: A consensus opinion. Infect Med. 1999;16:29–33
  34. Paediatrics. 1998;102:531–537
  35. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Paediatr Infect Dis J. 2000;19:1068–1071
  36. Cohen AH, Sorrentino M, Powers T. Effectiveness of palivizumab for preventing serious RSV disease. J Respir Dis. 2000;2:S30–S32
  37. Hand, I, Boron, M, VanVeldhuisen, P, Synagis Outcomes Registry, Synagis (palivizumab) prophylaxis of respiratory syncytial virus (RSV) infection—Patient demographics and preliminary results from the 2000–2001 Synagis Outcomes Registry, 23–27 September 2001
  38. Groothuis JR. Safety and tolerance of palivizumab administration in a large northern hemisphere trial. Paediatr Infect Dis J. 2001;20:628–630
  39. Lacaze-Masmonteil, T, Rozè, J-C, Fauroux, B, et al., Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a palivizumab-prophylaxed cohort, Paediatr Pulmonol
  40. Oh, P, I, Lanctôt, K, L, Yoon, A, et al., Prophylaxis for respiratory syncytial virus in Canada: outcomes and utilization with palivizumab during the 1999–2000 season, Paediatr Infect Dis J
  41. van Kan, C, I, Eenhoorn, P, C, Zweens, M, J, Woltil, H, A, Baarsma, R, Palivizumab surveillance: An evaluation of RSV-related hospitalization of high-risk children after palivizumab prophylaxis in The Netherlands during the 1999–2000 RSV season, 23–27 September 2001
  42. Grässl, G, Andreou, A, Pinquier, D, et al., Efficacy and safety of palivizumab (Synagis) in preterm infants 29–32 weeks gestational age without chronic lung disease to prevent serious respiratory syncytial virus respiratory tract infection, 23–27 September 2001
  43. Lacaze-Masmonteil, T, Seidenberg, J, Mitchell, I, et al., Safety and therapeutic profile of palivizumab (Synagis) over a first and second respiratory syncytial virus season, 23–27 September 2001
  44. Grøgaard, J, Anagnostakis, D, Yurdakok, M, et al., Severity of respiratory syncytial virus disease in children prophylaxed the previous season, 23–27 September 2001
  45. Simoes, E, New Therapeutic Approaches in RSV Infection: Vaccines and Prophylaxis?, Sept 23, 2001, http://www.ersnet.org/ers_pp/media_player/pages/liste.asp#7
  46. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Paediatr Adolesc Med. 2000;154:55–61
  47. Greenough A, Cox S, Alexander J. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child. 2001;85:463–468
  48. Carbonell-Estrany X, Quero J, Bustos G. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: A prospective study. Paediatr Infect Dis J. 2000;19:592–597
  49. Carbonell-Estrany X, Quero J. RSV hospitalization rates in premature infants born over two consecutive seasons. Paediatr Infect Dis J. 2001;20:874–879
  50. Cohen, A, H, Bomar, R, Cohen, L, E, et al., RSV prophylaxis using palivizumab in 86 high-risk children, outside of AAP Red Book Guidelines, April 28-May 1, 2001
  51. Hall CB, Douglas Jr RG, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis. 1980;141:98–102
  52. Cox RA, Rao P, Brandon-Cox C. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. J Hosp Infect. 2001;48:186–192
  53. Salcedo S, Vinzo J, Calico I. Administration of palivizumab (monoclonal antibodies against respiratory syncytial virus) during a nosocomial outbreak in a neonatal unit. Prenatal and Neonatal Medicine. 2000;5:180
  54. Hirsch, R, L, Sorrentino, M, D, Boron, M, L, Outcomes in infants receiving more than five doses of palivizumab for RSV prophylaxis, 23–27 September 2001
  55. Cohen, A, Hirsch, R, L, Sorrentino, M, Top Jr, F, H, Carlin, D, McClain, B, First year experience using Synagis® palivizumab humanized monoclonal antibody for protection from RSV lower respiratory tract infection, 1999
  56. Top FH, McClain JB, Leath C, Carlin D. Safety of Synagix (palivizumab) during first season of use. Prenatal and Neonatal Medicine. 2000;5:53

PII: S0954-6111(02)91296-5

doi: 10.1053/rmed.2002.1296

Respiratory Medicine
Volume 96 , Pages S15-S24 , April 2002

Article Tools